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Abstract
Purpose: To demonstrate fast treatment planning feasibility of stereotactic body
radiation therapy (SBRT) for centrally located lung tumors on Halcyon Linac
via a previously validated knowledge-based planning (KBP) model to support
offline adaptive radiotherapy.
Materials/methods: Twenty previously treated non-coplanar volumetricmodulated arc therapy (VMAT) lung SBRT plans (c-Truebeam) on SBRTdedicated C-arm Truebeam Linac were selected. Patients received 50 Gy in
five fractions. c-Truebeam plans were re-optimized for Halcyon manually (mHalcyon) and with KBP model (k-Halcyon).Both m-Halcyon and k-Halcyon plans
were normalized for identical or better target coverage than clinical c-Truebeam
plans and compared for target conformity, dose heterogeneity, dose fall-off, and
dose tolerances to the organs-at-risk (OAR). Treatment delivery parameters and
planning times were evaluated.
Results: k-Halcyon plans were dosimetrically similar or better than m-Halcyon
and c-Truebeam plans. k-Halcyon and m-Halcyon plan comparisons are presented with respect to c-Truebeam. Differences in conformity index were statistically insignificant in k-Halcyon and on average 0.02 higher (p = 0.04) in
m-Halcyon plans. Gradient index was on average 0.43 (p = 0.006) lower and
0.27 (p = 0.02) higher for k-Halcyon and m-Halcyon, respectively. Maximal
dose 2 cm away in any direction from target was statistically insignificant. kHalcyon increased maximal target dose on average by 2.9 Gy (p < 0.001). Mean
lung dose was on average reduced by 0.10 Gy (p = 0.004) in k-Halcyon and
increased by 0.14 Gy (p < 0.001) in m-Halcyon plans. k-Halcyon plans lowered
bronchial tree dose on average by 1.2 Gy. Beam-on-time (BOT) was increased
by 2.85 and 1.67 min, on average for k-Halcyon and m-Halcyon, respectively.
k-Halcyon plans were generated in under 30 min compared to estimated dedicated 180 ± 30 min for m-Halcyon or c-Truebeam plan.
Conclusion: k-Halcyon plans were generated in under 30 min with excellent
plan quality. This adaptable KBP model supports high-volume clinics in the
expansion or transfer of lung SBRT patients to Halcyon.
KEYWORDS
coplanar geometry, Halcyon Linac, KBP model, lung SBRT, non-coplanar VMAT
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INTRODUCTION

Surgical resection is an important treatment for earlystage nonsmall-cell lung cancer (NSCLC) patients.However, many patients are inoperable due to comorbidities, refuse surgical resection, or present with a high
chance of post-operative morbidity.1,2 For these NSCLC
patients, stereotactic body radiation therapy (SBRT)
has become an extremely effective curative treatment
modality.2 Compared to poor tumor local-control rates
from conventional lung radiotherapy (60%–70% local
failure rates), lung SBRT has provided very high localcontrol rates up to 97% (median, 3 years actuarial) with
less treatment-related toxicity compared to surgery.1–4
To deliver high-quality lung SBRT treatments, a precise delivered dose must be highly conformal around
the tumor with a steep dose gradient to limit intermediate dose spillage.5 This can be accomplished using
traditional 3D conformal radiation therapy (3D-CRT),
intensity-modulated radiation therapy (IMRT), or more
recently via manually generated volumetric-modulated
arc therapy (VMAT) plans.6–8 Delivering lung SBRT
with VMAT provides enhanced dosimetric benefits and
faster treatments that may aid in patient compliance.7,8
Currently, VMAT lung SBRT treatment is being delivered with flattening filter-free (FFF) beams using an
SBRT-dedicated C-arm linac.2,9–11 FFF beams provide
significantly higher dose rates, less out-of -field scatter dose, less electron contamination, and better target coverage at the tumor–lung interface in comparison
to flattened beams.11 These additional benefits translate to superior treatment in a shorter overall treatment
time.
For fast patient throughput and the advancement
of standard radiation treatments to the under-served
communities, Varian Medical Systems (Palo Alto, CA)
recently introduced a new jawless, single energy, and
ring-mounted coplanar restricted Halcyon (V2.0) medical linear accelerator.12 The Halcyon Linac is equipped
with a 6X-FFF beam with a maximum dose rate set-

FIGURE 1

ting of up to 800 MU/min, much lower than the 6MVFFF (up to 1400 MU/min) beam on an SBRT-dedicated
Truebeam Linac. The Halcyon Linac has a relatively
softer beam with a mean energy and nominal maximum depth dose of 1.3 MeV and at 1.3 cm, compared to the corresponding 6MV-FFF beam on Truebeam of 1.4 MeV and 1.5 cm. Additionally, Halcyon’s
ring-mounted gantry design offers a fourfold increase
in gantry rotation speed when compared to Truebeam
and is equipped with a new design of 1 cm wide duallayered stacked and staggered multileaves collimator
(MLC) (see Figure 1).13,14 This design restricts the field
size to 28 × 28 cm2 ; however, the stacked and staggered MLC design offers complete leaf interdigitation
and allows for MLC travel all the way to 28 cm. With
a less rounded MLC leaf design, the Halcyon boasts
a small dosimetric leaf gap of 0.1 mm and ultra-low
leakage and transmission around 0.4%.14,15 This novel
MLC design offers leaf speed of up to 5.0 cm/s with
an effective equivalent 5 mm MLC resolution at the
treatment isocenter. Additionally, target localization is
potentially improved with the Halcyon onboard imager
because it has an advanced image reconstruction algorithm that can iteratively reconstruct a pre-treatment
conebeam CT.16 This reconstruction can be acquired
in less than 15 s due to the increased gantry speed.
Moreover, the new “one-step patient set up” approach
includes automatically applied isocenter shifts that will
significantly reduce patient set up times.12 One drawback to the Halcyon is that all treatment plans are
restricted to coplanar beam geometry, whereas SBRTdedicated C-arm linacs allow for larger range of noncoplanarity.
Currently, highly conformal clinical VMAT lung SBRT
plans are generated using a manually optimized inverse
planning technique. An issue with manual planning is
that the quality of the final plan depends on individual patient anatomy, planning experience, and available
treatment planning time.17,18–24 This potentially leads to
interplanner variability (i.e., plans with varied dosimetric

Beams-eye-view and description of the new stacked and staggered MLC design on the Halcyon Linac
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quality). Knowledge-based planning (KBP) has become
a clinically feasible approach for generating high-quality
treatment plans and aims to mitigate the issues associated with manual planning by standardizing treatment
plans and removing interplanner variability.18 This is
commonly accomplished by using a model library of previously generated high-quality clinical plans to predict
new treatment parameters.19 KBP improves plan quality and drastically reduces treatment planning and will
shorten ‘simulation-to-treatment’ time down to as few
as three working days.25 Our center uses Varian RapidPlan dose–volume histogram estimation algorithm as
our KBP engine. In the past, a few investigators have
shown that KBP may help to create dosimetrically superior or similar lung SBRT plans when compared to manual planning for traditional SBRT-dedicated C-arm linac
treatments.21–25
Halcyon has been shown to provide fast and effective treatment in the setting of conventionally fractionated cranial, head and neck, prostate, and breast
treatments.26–28 However, due to the lack of lung SBRT
training datasets on Halcyon, there is no literature that
describes training and clinically validating a KBP model
for lung SBRT. This prompted us to evaluate the feasibility of generating lung SBRT plans for centrally located
tumors as per RTOG-0813 criteria29 on the Halcyon
Linac using a previously validated KBP model using
high-quality non-coplanar Truebeam VMAT plans. It has
previously been demonstrated that lung SBRT using a
coplanar geometry produces similar patient outcomes
compared to non-coplanar treatments and that it is feasible to treat lung SBRT on the Halcyon Linac.30,31 The
aim of this study was to evaluate the capabilities of
KBP modeling techniques to produce coplanar VMAT
plans of similar or better quality on ring-mounted Halcyon when compared to traditional non-coplanar lung
SBRT treatments delivered on a C-arm Truebeam. We
additionally sought to demonstrate whether the Halcyon
can overcome coplanar restrictions with the aid of a previously trained KBP model in the treatment of centrally
located lung tumors using SBRT.

2
2.1

MATERIALS AND METHODS
Patient selection

Institutional review board approval was obtained to conduct this retrospective study. The previously validated inhouse lung SBRT KBP model that was built using highly
conformal non-coplanar VMAT plans with a patient
cohort of 86 patients was adopted for this study. Details
of the model generation have been published.25 Twenty
new patients who were previously treated to 50 Gy in five
fractions for early-stage I-II NSCLC on SBRT-dedicated

Truebeam Linac using non-coplanar VMAT plans were
retrospectively selected to further validate this model on
Halcyon Linac.

2.2

Clinical plans (c-Truebeam)

Patients in this cohort were primarily immobilized using
the Body Pro-Lock system (CIVCO system, Orange City,
IA, USA) in the supine position with their arms above
the head and abdominal compression. A free-breathing
3DCT scan was then performed and a gross target
volume (GTV) was delineated followed by a planning
target volume (PTV) with expanded margins of 1.0 cm
superior/inferior and 0.5 cm laterally from the GTV. If a
patient was unable to undergo abdominal compression,
a respiration-correlated 4DCT scan using the Varian
RPM system (version 1.7) was performed. Maximum
intensity projection (MIP) images were derived from the
4DCT scan, and the images were co-registered to the
free-breathing 3DCT images to delineate an internal target volume (ITV), therefore, the GTV = ITV. The PTV was
created by expanding the ITV by 0.5 cm in all directions
per SBRT protocol guidelines. For these patients, all
treatment planning was performed on the free-breathing
CT dataset. As specified by the RTOG-0813 requirements, all relevant organs-at-risk (OAR) were contoured
(e.g., total lungs, spinal cord, ribs, heart, esophagus
brachial plexus, and skin). For the robust validations
of this model, we have included variable tumor sizes
and locations on both lungs’ geometries as shown in
Table 1.
All patients were treated with a highly conformal
plan using non-coplanar VMAT geometry on Truebeam
Linac using a 6MV-FFF beam with a maximum dose
rate of 1400 MU/min. On average three to six noncoplanar partial arcs (±5–12◦ couch rotations) were utilized with average arc length of approximately 200◦
and patient-specific collimator angles were selected
to minimize the MLC tongue and groove effect (jawtracking enabled). Truebeam couch and SBRT board
were inserted. Isocenter was placed in the center of
the PTV and the dose was prescribed to the 60%–80%
isodose line and normalized to ensure at least 95% of
the PTV received the full prescription dose of 50 Gy in
five fractions. All hot-spots (average: 120%–140%) were
constrained to be within the GTV. Clinical plans were
inversely optimized using the photon optimizer (PO version 13.0 or 15.0) with final dose calculation performed
using AcurosXB with a 1.25 mm calculation-grid size
(CGS) with tissue heterogeneity corrections.32,33 Dose
to medium reporting mode was enabled per our linac
calibration. These patients were treated every other day.
On the treatment day, an online pretreatment conebeam CT scan was performed for patient set-up corrections.
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Patient cohort and tumor characteristics

Tumor location

Population, n

Overall patient cohort

20

GTV size (cc)

PTV size (cc)

9.7 ± 13.4 (0.1–61.2)

32.6 ± 25.8 (7.5–114.3)

RLL

6

13.5 ± 21.7 (0.1–61.2)

37.0 ± 36.9 (7.5–114.3)

RUL

5

12.8 ± 8.1 (1.6–22.1)

43.1 ± 22.1 (11.2–71.7)

LLL

4

4.2 ± 1.7 (2.8–7.0)

24.1 ± 8.6 (12–33.1)

LUL

5

6.6 ± 5.5 (1.0–14.8)

23.7 ± 14.5 (9.7–51.3)

Note: Overall, the patient cohort and each tumor geographical location and tumor sizes are presented as a total number (n) and mean ± SD (range), respectively.
Abbreviations: GTV, gross tumor volume; LLL, left lower lobe; LUL, left upper lobe; PTV, planning target volume; RLL, right lower lobe; RUL, right upper lobe.

2.3

m-Halcyon plans

For comparison, all c-Truebeam lung SBRT plans were
manually reoptimized on Halcyon (m-Halcyon) with
identical arc lengths and collimator rotations but using
coplanar geometry. Additionally, in most cases the total
number of arcs were identical to c-Truebeam plans. The
Truebeam couch was removed and the Halcyon couch
and SBRT board were inserted. As previously described,
m-Halcyon plans were reoptimized with the same calculation algorithms (with corresponding CGS) and identical planning objectives when compared to c-Truebeam
plans. No jaw-tracking option is available on this jawless
Halcyon. The m-Halcyon plans received the same target
coverage as the clinical c-Truebeam plans.

2.4

k-Halcyon plans

c-Truebeam plans were reoptimized automatically on
Halcyon (k-Halcyon) using a previously validated KBP
RapidPlan model. The previous KBP model was developed using 86 high-quality non-coplanar VMAT training plans that were previously treated on the Truebeam
Linac. All these patients received 50 or 55 Gy in five fractions and treatment was delivered every other day. Additionally, 20 new independent patient’s plans were used
for KBP model validation. At the time of this manuscript
preparation,this model has been deployed clinically on a
limited basis. The planning geometry of the k-Halcyon is
identical to m-Halcyon. k-Halcyon plans used the same
calculation algorithms and corresponding CGS but with
the automatic planning constraints generated by the
previously validated non-coplanar KBP model. The kHalcyon plans received the same target coverage as the
clinical m-Halcyon plans.

2.5

index (CI), and the ratio of the 50% isodose volume to
the PTV volume known as the gradient index (GI). Additionally, the maximal dose at 2 cm away from the PTV
in any direction (D2cm) was assessed for intermediate
dose fall-off. Supplemental to the RTOG-0813 criteria, our institution records the gradient distance (GD)
defined as the average distance between the 100% and
50% isodose line to further quantify intermediate dose
spillage. Moreover, the heterogeneity index (HI), ratio of
PTV maximal dose in cGy and prescription dose were
used to assess hot-spots of each plan. In addition to
target and plan complexity metrics, dose to OAR was
tracked and documented for maximal and volumetric dosing per RTOG-0813 criteria. These structures
include: spinal cord, ipsilateral brachial plexus, skin, total
lung-PTV, esophagus, heart, and trachea. Plan complexity was simply assessed by recording total number
of monitor units (MU) and modulation factor (MF). The
MF is defined as the total number of MU divided by the
prescription dose in cGy and the corresponding beamon-time (BOT) was calculated using total MU divided by
the delivered dose rate for each plan. Moreover, overall
treatment planning time and results of independent
dose verification via a second physics check Monte
Carlo (MC) routine were recorded.34 To collect and
statistically compare these metrics, an in-house data
collection routine was developed using Eclipse Visual
Scripting (Varian Medical Systems, Palo Alto, CA, USA)
and MATLAB (Math Works, Natick, MA, USA). Statistical
analysis was performed with Microsoft Excel (Microsoft
Corp., Redmond, WA, USA) using a paired student t-test
with p < 0.05 signifying statistical significance.

3

RESULTS

Target coverage and intermediate
3.1
dose fall-off

Plan dosimetric evaluation

All plans were dosimetrically evaluated for target conformity, gradient indices, and dose to OAR with RTOG-0813
protocol’s requirements. This included the ratio of prescription isodose volume to the PTV volume, conformity

Plan quality and target coverage indices are displayed
in Table 2. All results are presented for both m-Halcyon
and k-Halcyon plans with respect to c-Truebeam plans.
Both m-Halcyon and k-Halcyon produced clinically
insignificant differences in conformity indices indicating
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TA B L E 2 Evaluation of plan quality and target coverage indices for all 20 lung stereotactic body radiation therapy (SBRT) validation cases
including original c-Truebeam plans

m-Halcyon

c-Truebeam

k-Halcyon vs.
m-Halcyon,
p value

k-Halcyon vs.
c-Truebeam,
p value

m-Halcyon vs.
c-Truebeam,
p value

Target

Parameter

k-Halcyon

PTV

CI

1.01 ± 0.02

1.03 ± 0.04

1.01 ± 0.04

n.s.

n.s.

0.04

HI

1.19 ± 0.02

1.16 ± 0.03

1.14 ± 0.04

<0.001

<0.001

n.s.

GI

4.22 ± 1.2

4.92 ± 1.3

4.65 ± 1.2

<0.001

0.005

0.02

D2cm (%)

50.8 ± 4.9

51.4 ± 5.0

50.5 ± 4.4

n.s.

n.s.

n.s.

GD (cm)

1.06 ± 0.2

1.17 ± 0.2

1.11 ± 0.2

<0.001

0.02

0.002

Note: Mean ± SD and p-values were reported. Significant p-values are highlighted in bold.
Abbreviations: CI, conformity index; D2cm, the maximal dose at 2 cm away from the PTV in any direction; GD, gradient distance; GI, gradient index; HI, heterogeneity
index; n.s., not significant; PTV, planning target volume.

dose was 55.8 ± 1.61 Gy (53.7–60.6 Gy),57.8 ± 1.81 Gy
(55.7–65.0 Gy), and 55.7 ± 3.0 Gy (53.9–68.3 Gy) for mHalcyon, k-Halcyon, and c-Truebeam plans, respectively.
Additionally,on average k-Halcyon plans provided higher
GTV minimum dose by 1.2 Gy (p = 0.04), maximum up
to 7.6 Gy in some cases.

3.2

F I G U R E 2 Average doses to planning target volume (PTV) and
gross tumor volume (GTV) (in Gy) for 20 lung stereotactic body
radiation therapy (SBRT) validation cases including clinically treated
c-Truebeam plans. Near minimum PTV (D99%) dose was similar
across c-Truebeam, m-Halcyon, and k-Halcyon plans. In general,
k-Halcyon provided higher average dose to PTV and GTV relative to
both m-Halcyon and k-Halcyon plans

similar target coverage. The m-Halcyon plans, on average, produced less homogenous plans as indicated by
the increase of 0.27 in GI (p = 0.02), whereas k-Halcyon
plans provided more homogeneity in target coverage
by reducing the GI on average 0.43 (p < 0.005). Across
both plans, D2cm differences were statically insignificant; however, the GD was much higher in m-Halcyon
plans and lower in k-Halcyon plans. This potentially
indicates less intermediate dose spillage when using
KBP with Halcyon Linac.
Figure 2 displays the average near minimum (D99%)
and mean PTV dose including the average minimum,
mean, and maximal doses to GTV for all three plans.
Qualitatively, the near minimum dose to PTV was similar
across all three plans (p = n.s.), however k-Halcyon was
able to increase dose across all other metrics indicating
slight dose escalation may be achievable on the Halcyon
using KBP model. This is in part due to selected target
dosing objectives chosen by the KBP model and to the
coplanarity treatments on Halcyon plans.The PTV mean

Dose to OAR

Maximal and volumetric doses to OAR were recorded
per protocol guidelines and the pairwise differences (in
Gy) with respect to clinical c-Truebeam plans are presented in Figure 3. Positive values indicate that both mHalcyon and k-Halcyon plans provided higher doses to
OAR compared to c-Truebeam plans. In many cases,
k-Halcyon plans helped reduce doses to OAR more
than m-Halcyon plans, although these small differences
may not be clinically significant. However, this finding
supports the premise that k-Halcyon plans on average will be dosimetrically similar or superior to clinical
c-Truebeam plans and to m-Halcyon. One interesting
value to note is that k-Halcyon on average reduced the
maximum rib dose by 1.9 Gy (p = 0.003), maximum up
to 6.3 Gy in some cases.
Dose to normal lung was evaluated using V5Gy,
V10Gy, V20Gy and mean lung dose (Gy) as all of these
metrics have been correlated to radiation-induced pneumonitis and recently, may correlate with overall survival
in stage I lung cancer.35–37 These results are shown in
Table 3. k-Halcyon plans on average reduced all normal
lung dosing metrics whereas m-Halcyon increased values when compared to c-Truebeam plans. The largest
differences in dose to normal lung were recorded for
V5Gy. There was a 0.4% decrease and a 0.6% increase
of dose for k-Halcyon and m-Halcyon, respectively.

3.3

Planning times and plan complexity

The k-Halcyon planning time was less than 30 min. This
is compared to the estimated dedicated planning time
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F I G U R E 3 Pairwise dose differences (in Gy) of maximal and volumetric dose to organs-at-risk (OAR) for k-Halcyon and m-Halcyon plans
with respect to c-Truebeam plans. Positive values indicate respective plans on average provided a higher dose to OAR compared to c-Truebeam
plans. k-Halcyon plans across many dosing metrics delivered lower OAR doses than m-Halcyon including an average 0.74 Gy reduction in
maximal dose to heart

TA B L E 3 Evaluation of normal lung dosing for 20 lung stereotactic body radiation therapy (SBRT) validation cases including original
c-Truebeam plans

Lungs-PTV

k-Halcyon

m-Halcyon

c-Truebeam

k-Halcyon vs.
m-Halcyon,
p value

V5Gy (%)

12.0 ± 5.6

13 ± 5.6

12.4 ± 5.6

<0.001

k-Halcyon vs.
c-Truebeam,
p value

m-Halcyon vs.
c-Truebeam,
p value

n.s.

<0.001
<0.001

V10Gy (%)

6.9 ± 4.2

7.6 ± 4.4

7.2 ± 4.3

<0.001

0.01

V20Gy (%)

2.7 ± 2.1

3.0 ± 2.3

2.8 ± 2.2

<0.001

0.002

0.02

MLD (Gy)

2.5 ± 1.2

2.7 ± 1.3

2.6 ± 1.2

<0.001

0.004

<0.001

Mean ± SD and p-values were reported. Significant p-values are highlighted in bold.
Abbreviations: MLD, mean lung dose; n.s., not significant.

of 180 ± 30 min (for an experienced planner) to manually create a high-quality non-coplanar VMAT lung SBRT
plan. This estimation solely accounts for dedicated planning time and no other parts of the planning workflow
such as contouring. In practice, this is not feasible as
the planners frequently work on multiple plans simultaneously, must wait for physician’s time for contouring, or
other various checks prior to the final plan approval.Plan
complexity was assessed using total MU and its derived
metrics that include MF and the corresponding BOT
(Table 4) as described above. There was no statistically
significant difference in MU between m-Halcyon and cTruebeam plans; however, MU increased for k-Halcyon
plans by 939 MU on average (p < 0.001) compared
to c-Truebeam plans. This corresponds to an increased
MF of 0.94 (p < 0.001) indicating k-Halcyon plans are
modulated higher than both manual plans. Despite this
increase of modulation, no clinically significant differences in agreement between the Eclipse TPS and the
second check MU calculated dose were observed. Due
to maximum dose rate restrictions (800 MU/min), BOT
inherently increases by 2.86 and 1.66 min,on average,in

k-Halcyon and m-Halcyon plans relative to c-Truebeam,
respectively.

3.4

LUL example case

Figures 4 and 5 present an example patient with a left
upper lobe (LUL) lesion with the typical findings. The
cumulative dose–volume histogram and corresponding
three-plane view through the isocenter are presented
for each plan. As shown in the dose volume histogram
(DVH), the k-Halcyon plan (triangles) is able to escalate the GTV minimum dose when compared to both
m-Halcyon (circles) and c-Truebeam (squares). In this
case, relative to c-Truebeam, GTV minimum dose was
escalated by 4.6 Gy with minimal to no additional cost
to OAR sparing (Figure 4). For example, the esophagus
(blue) is the most proximal OAR to the target. The
k-Halcyon plan provided at least 1.3 Gy lower maximal
esophageal dose compared to the c-Truebeam plan.
This dose sparing was accomplished in conjunction
with a clinically significant GTV dose escalation. Similar
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F I G U R E 4 Cumulative dose–volume histogram for an example left upper lobe (LUL) patient is presented. The cumulative DVH displays
selected organs-at-risk (OAR) and targets that include: gross tumor volume (GTV) (red), planning target volume (PTV) (pink), trachea (orange),
ribs(green), esophagus (blue), and lungs-PTV (brown) for the k-Halcyon (triangles), m-Halcyon (circles), and c-Truebeam plan (squares). In this
case, the k-Halcyon plan was able to significantly increase GTV dose while maintaining similar or better OAR sparing with similar intermediate
dose spillage relative to both m-Halcyon and c-Truebeam plan

F I G U R E 5 Corresponding all three views for the example left upper lobe (LUL) patient seen in Figure 4. Each view includes the same OAR
and targets represented in the previously shown DVH. Note the k-Halcyon plan displays a larger central hot-spot when compared to both
c-Truebeam and m-Halcyon plans. In all plans, tight radio-surgical isodose color-wash distributions are shown with the blue representing 50%
prescription dose

VISAK ET AL.
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TA B L E 4 Evaluation of plan delivery metrics for 20 lung stereotactic body radiation therapy (SBRT) validation cases including original
Truebeam plans

Parameter

k-Halcyon

m-Halcyon

c-Truebeam

k-Halcyon vs.
m-Halcyon,
p value

k-Halcyon vs.
c-Truebeam,
p value

m-Halcyon vs.
c-Truebeam,
p value

Total MU

4076 ± 608

3126 ± 745

3137 ± 873

<0.001

<0.001

n.s.

MF

4.08 ± 0.6

3.12 ± 0.7

3.14 ± 0.9

<0.001

<0.001

n.s.

BOT (min)

5.10 ± 0.8

3.90 ± 0.9

2.24 ± 0.6

<0.001

<0.001

<0.001

MC second check
results (%)

98.6 ± 1.9

99.9 ± 2.4

98.4 ± 2.0

n.s.

n.s.

0.03

Mean ± SD and p-values were reported. Significant p-values are highlighted in bold.
Abbreviations: BOT, beam-on-time; MC, Monte Carlo; MF, modulation factor; MU, monitor units; n.s., not significant.

intermediate dose spillage can be seen (Figure 5) for
all three plans, with D2cm values reported to be 45%
for both k-Halcyon and m-Halcyon plans compared to
46% in the c-Truebeam plan.

4

DISCUSSION

This study appears to be the first to evaluate the use of
a KBP model for SBRT treatment of centrally located
early-stage NSCLC patients using the ring-mounted
coplanar Halcyon Linac. While manually generated lung
SBRT plans on Halcyon were dosimetrically comparable
to clinically treated plans on SBRT-dedicated Truebeam
Linac, the lung SBRT KBP model (originally trained and
validated using non-coplanar Truebeam VMAT plans)
was able to generate high-quality coplanar plans on
Halcyon. This was accomplished with a much shorter
treatment planning time and eliminated interplanner
variability. This KBP model offers a viable alternative
to an SBRT-dedicated C-arm linac for selected lung
SBRT patients. It may also be inferred that these plans
were of similar quality to the Truebeam clinical plans
because of the better utilization of the improved SX2
MLC on Halcyon. Additionally, dose to normal lung was
significantly improved in k-Halcyon compared to both
m-Halcyon and c-Truebeam plans.
A commercially available treatment planning system
RayStation (RaySearch Laboratories, Stockholm, Sweden) offers a unique feature termed “fall-back (FB)”
planning module for adaptive replanning.38 This module
enables generation of 3D-CRT, IMRT, or VMAT plans
based on reference plans for any treatment modality
using a dose-mimicking algorithm with minimal planner time and effort. Recently, a few investigators have
demonstrated that the FB planning module can convert
Helical Tomotherapy plans to C-arm linac for various
sites including conventionally fractionated treatment
to brain tumors, head and neck, pelvis, prostate, and
lung tumors.39,40 It was reported that these FB plans
were dosimetrically comparable to the original clinical plans and allowed for the fast and easy transfer
of patients between treatment modalities during an

unforeseen period of machine downtime.39,40 For
instance, Yuan et al.40 showed that FB plans would typically be generated on average for one to five fractions
of the conventionally fractionated treatment course in
the event of machine breakdown. Furthermore, their
results suggested that an overall <1% dose variation
can be achieved on target coverage and dose to OAR
on FB plans. These FB plans were typically generated
in 10–20 min per case so that the patient can be
treated on another machine. As of now, this feature is
not available in Varian Eclipse. In the case of longer
machine downtime, a full re-plan on another machine
would be required, resulting in significant treatment
course delay. Our KBP model could emulate the ability
of the RayStation FB planning module and enable our
clinic to transfer lung SBRT patients between Halcyon
and Truebeam Linacs (if required) by generating a
similar quality plan in less than 30 min planning time.
Furthering this thought, various treatment units are not
always beam matched in busy and larger clinics or all
commissioned to a golden beam dataset. Therefore,
utilizing a KBP model would be vital to transferring these
patients between the modalities the same or next day,
reducing the chance of delaying the treatment course.
There are some limitations to this study and to the Halcyon Linac. An important limitation is that, at the time of
this manuscript preparation, our clinic has treated a limited number of centrally located lung SBRT patients on
Halcyon.In the future,as more select lung SBRT patients
are treated on Halcyon,it would be interesting and useful
to include these patients in the training dataset to form
a hybrid model with the clinical Truebeam SBRT plans.
This may further improve the k-Halcyon’s model performance and may potentially create even higher quality
lung SBRT plans for prospective patients. Mechanically
speaking, our Truebeam Linac is equipped with a perfect pitch couch with 6-degree of freedom (6DOF) couch
corrections that allows for more accurate target localization compared to the Halcyon Linac. Additionally, for
6MV-FFF beam, the Truebeam Linac allows for a higher
dose rate of maximum up to 1400 MU/min while the
Halcyon maximum achievable dose rate of 800 MU/min
(increasing the BOT).This dose–rate discrepancy allows
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for treatments will be still clinically practical as a fivefraction treatment scheme required relatively lower MU
per fraction to be delivered the prescribed dose. Meaning, this added BOT can be offset with regard to overall treatment time using the Halcyon’s “one-step patient
set-up” capabilities as described above. However, as of
now, Halcyon may not be suitable to treat lung SBRT
patients with other commonly used extremely large fraction sizes (e.g., 54–60 Gy in three fractions or 30–34 Gy
in one fraction)41–43 due to relatively longer treatment
time. Future work will include investigating the feasibility of utilizing KBP models to generate lung SBRT plans
with other fractionation schemes for both centrally and
peripherally located lung tumors on Halcyon Linac.

5

CONCLUSION

This study reports on the plausibility of generating lung
SBRT plans for centrally located early-stage NSCLC
patients on ring-mounted Halcyon Linac using a previously trained and validated Truebeam KBP model. It has
been demonstrated that the KBP model can be used
to generate high-quality lung SBRT plans on the Halcyon Linac that are dosimetrically equivalent or better
quality when compared to manually generated Halcyon
and SBRT-dedicated Truebeam plans. This lung SBRT
model is capable of quickly generating SBRT plans to
support a curative SBRT treatment for centers by assuring that treatments are delivered in a safe and consistent manner potentially allowing for offline adaptive
re-planning, if needed. Additionally, the results of this
study indicate that KBP models can be cross-compatible
between SBRT-dedicated C-arm and O-ring linacs for
lung SBRT. It is clinically useful to enable a clinic’s ability to facilitate a smooth transfer of patients between
treatment machines as it will ensure minimal to no treatment course disruption. This model can be shared and
may provide confidence in centers equipped solely with
the Halcyon Linac in the treatment of lung SBRT in the
future. It may also be a great option for diverse centers
with a high SBRT volume, or for patients who require an
immediate SBRT.
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